← Back to Screener
Replimune Group, Inc. (REPL)
Price$9.47
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)-13.23%
Price vs S&P 500 (4W)132.69%
VGM Score68.45
Market Capitalization$781.96M
All Metrics
Book Value / Share (Quarterly)$2.64
P/TBV (Annual)1.11x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-3.55
Price vs S&P 500 (YTD)-10.73%
EPS (TTM)$-3.44
10-Day Avg Trading Volume9.99M
EPS Excl Extra (TTM)$-3.44
EPS (Annual)$-3.07
ROI (Annual)-50.70%
Cash / Share (Quarterly)$3.38
ROA (Last FY)-44.85%
EBITD / Share (TTM)$-3.53
ROE (5Y Avg)-38.68%
Cash Flow / Share (Annual)$-2.58
P/B Ratio3.71x
P/B Ratio (Quarterly)3.62x
Net Income / Employee (Annual)$-516,300
Net Interest Coverage (TTM)-63.50x
ROA (TTM)-72.22%
EPS Incl Extra (Annual)$-3.07
Current Ratio (Annual)7.95x
Quick Ratio (Quarterly)5.43x
3-Month Avg Trading Volume5.55M
52-Week Price Return-2.87%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$7.88
52-Week High$13.24
EPS Excl Extra (Annual)$-3.07
CapEx CAGR (5Y)0.45%
Tangible BV CAGR (5Y)56.96%
26-Week Price Return-5.30%
Quick Ratio (Annual)7.82x
13-Week Price Return34.52%
Total Debt / Equity (Annual)0.17x
Current Ratio (Quarterly)5.60x
Enterprise Value$731.63M
Book Value / Share Growth (5Y)1.51%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$6.28
3-Month Return Std Dev267.05%
Net Income / Employee (TTM)$-657,300
ROE (Last FY)-59.47%
Net Interest Coverage (Annual)-83.16x
EPS Basic Excl Extra (Annual)$-3.07
Total Debt / Equity (Quarterly)0.34x
EPS Incl Extra (TTM)$-3.44
ROI (TTM)-83.10%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$9.80
Price vs S&P 500 (52W)-27.24%
Year-to-Date Return-2.57%
5-Day Price Return5.22%
EPS Normalized (Annual)$-3.07
ROA (5Y Avg)-31.31%
Month-to-Date Return8.98%
Cash Flow / Share (TTM)$-3.02
EBITD / Share (Annual)$-3.22
LT Debt / Equity (Annual)0.11x
ROI (5Y Avg)-34.00%
LT Debt / Equity (Quarterly)0.23x
EPS Basic Excl Extra (TTM)$-3.44
P/TBV (Quarterly)1.32x
P/B Ratio (Annual)1.81x
Book Value / Share (Annual)$5.39
Price vs S&P 500 (13W)26.26%
Beta0.90x
Revenue / Share (TTM)$0.00
ROE (TTM)-102.69%
52-Week Low$1.50
mGradeB
vgmGradeB
Show chart for
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.14
4.14
2.54
2.62
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
REPLReplimune Group, Inc. | — | — | B | $9.47 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Replimune is a clinical-stage biotechnology company developing oncolytic immunotherapies for solid tumors using its proprietary RPx platform, which leverages an engineered HSV-1 virus to maximize immune activation against cancer. The company's pipeline includes three product candidates: RP1, RP2, and RP3. Replimune operates primarily in the United States with additional operations in the UK.